Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation

Next Previous
X
Search
Trial Profile

Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms LUX-Bladder 1
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 15 Dec 2023 Results assessing the efficacy and safety of second-line afatinib 40 mg/d in patients with metastatic urothelial carcinoma with ERBB1-3 alterations, published in the British Journal of Cancer
    • 05 Sep 2019 Status changed from active, no longer recruiting to completed.
    • 13 May 2019 Planned End Date changed from 30 Mar 2020 to 2 Sep 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top